Background-Patients with severe aortic stenosis at increased surgical risk continue to experience compromised long-term survival despite successful transcatheter aortic valve implantation. We used time-related pathways in a multistate analysis to identify predictors of adverse long-term outcome in patients who underwent transcatheter aortic valve implantation. Methods and Results-In a cohort of 389 patients with a mean age of 82.4±5.8 years and a STS score of 6.8±5.3 undergoing transcatheter aortic valve implantation between 2007 and 2011, multistate analysis was used to estimate mortality and stroke taking into account intercurrent events including kidney injury and the composite of access site and bleeding complications (ABC). Transapical access emerged as a predictor of kidney injury (hazard ratio [HR], 2.12; 95% confidence interval [CI] 1.00-4.47) and ABC (HR, 1.78; 95% CI, 1.07-2.96), but had no impact on the risk of stroke or death. Body mass index ≤20 kg/m 2 increased the risk of stroke or death (HR, 2.64; 95% CI, 1.25-5.54). Age >80 years (HR, 3.15; 95% CI, 1.11-8.92), body mass index ≤20 kg/m 2 (HR, 4.11; 95% CI, 1.33-12.70), prior stroke (HR, 16.42; 95% CI, 3.63-74.21), and presence of atrial fibrillation at baseline (HR, 4.12; 95% CI, 1.87-9.97) increased the risk of stroke and death after an intercurrent event of ABC. Conclusions-A body mass index ≤20 kg/m 2 was identified as a primary predictor of stroke and death after transcatheter aortic valve implantation during long-term follow-up, whereas transapical access emerged as a predictor of kidney injury and ABC. Age >80 years, body mass index ≤20 kg/m 2 , prior stroke, and presence of atrial fibrillation at baseline increased the risk of stroke and death after an intercurrent event of ABC. (Circ Cardiovasc Interv. 2012;5:856-861.)
C ontrary to therapeutic interventions among low-risk patients, high-risk patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) remain at considerable risk for mortality during long-term follow-up despite elimination of a high transaortic pressure gradient. 1, 2 Aside from procedural risks which are captured within established surgical risk scores, long-term survival after successful TAVI largely depends on comorbidities. To provide selection criteria for patients to benefit most from TAVI, it is therefore necessary to identify not only predictors of peri-procedural risk but also of potentially adverse longterm clinical outcome.
Adverse events during long-term follow-up after TAVI have mostly been considered as independent clinical entities, disregarding the association and sequence of events as part of a degenerative disease process ultimately leading to death. Although TAVI adequately relieves mechanical obstruction attributable to aortic stenosis, coexisting morbidities continue to propel the degenerative disease process in a modified way across various transitions. Predictors of transitions in the clinical pathway of disease progression after TAVI during long-term follow-up have not been investigated so far.
Traditional outcome analyses consider clinical events as independent entities disregarding the sequence and inter-relationship of multiple adverse events and their impact on prognosis. This analytical approach ignores the time-dependent transition through different stages of adverse events and may underestimate the aggregate risk. Multistate analysis (MSA) considers intermediate clinical events as stages with transitions from 1 adverse event to another over time. Therefore, MSA provides an instrument to model the risk of clinical outcomes as specific transitions from TAVI through intermediate events until the end of follow-up or death. This analytical approach considers all events in aggregate and is of particular interest among patients undergoing TAVI because of the frequent presence of comorbidities increasing the risk of intermediate events.
Unlike traditional analysis treating all events separately, MSA integrates several events in a single analysis and provides risk estimates through different intermediate stages of disease. This time-dependent analysis accounts for the inter-relationship of different events along a pathway of disease progression and provides a holistic approach to outcome assessment.
We used time-related pathways in a MSA, incorporating intercurrent events including access site and bleeding complications (ABC) and Kidney Injury (KI) collectively to estimate the risk of stroke and death in patients with severe aortic stenosis undergoing TAVI.
Methods

Patient Population
Patients with severe aortic stenosis at increased risk for surgical aortic valve replacement who underwent TAVI were consecutively enrolled in a prospective single-center registry initiated in July 2007. Patients qualified for TAVI in the presence of a formal indication for aortic valve replacement therapy in combination with advanced age (≥80 years) and an increased risk for surgical aortic valve replacement attributable to comorbidities such as compromised left ventricular ejection fraction, severe pulmonary hypertension (pulmonary artery systolic pressure ≥60 mm Hg), chronic obstructive pulmonary disease (forced expiratory volume during 1 second <1.0), porcelain aorta, history of mediastinal radiation therapy, or frailty expressed by a body mass index (BMI) <18 kg/m2).
Procedures and Data Collection
TAVI was performed using the Medtronic CoreValve or the Edwards-SAPIEN bioprosthesis through a transfemoral, transapical, or transsubclavian approach according to instructions for use and anatomic characteristics as described previously. 3 Concomitant coronary artery disease with lesions subtending a significant area of ischemia was treated concomitantly or staged by percutaneous coronary intervention prior to TAVI.
All patients undergoing TAVI underwent a standardized follow-up protocol at 1, 6, and 12 months, and yearly thereafter. If necessary, hospital records and municipal civil registries were consulted to ascertain vital status. Medical records were systematically collected and all clinical events were adjudicated by a nonblinded clinical event committee consisting of cardiac surgeons and interventional cardiologists.
Definitions
All end points were defined according to the criteria published by the Valve Academic Research Consortium. 4 Cardiovascular (CV) death included any death attributable to a proximate cardiac cause or death of unknown cause, as well as all procedure-related deaths and death caused by noncoronary vascular conditions such as cerebrovascular disease, pulmonary embolism, or other vascular disease. Peri-procedural myocardial infarction was defined as new ischemic symptoms or ECG-signs in the presence of elevated cardiac biomarkers (2 or more postprocedure samples that were >6-8 hours apart with a 20% increase in the second sample and a peak value exceeding 10× the 99th percentile upper reference limit, or a peak value exceeding 5× the 99th percentile upper reference limit with new pathological Q waves in at least 2 contiguous leads) within 72 hours after the index procedure. Major stroke involved a rapid onset of focal or global neurological deficit of ≥24 hours duration requiring therapeutic intervention, or documentation of a new intracranial ischemic or hemorrhagic defect by means of a magnetic resonance imaging or computed tomography-scan. For the purpose of this analysis, major stroke and all-cause mortality have been combined to a single composite event. The modified Risk, Injury, Failure, Loss, End-stage kidney disease classification was applied for the definition of KI which was based on changes in serum creatinine up to 72 hours after the procedure. Stage 1 was defined as an increase of serum creatinine to 150% to 200% (or an increase of ≥26.4 µmol/L), stage 2 was determined by an increase of the baseline creatinine to 200% to 300%, and stage 3 was considered in case of an increase in creatinine of ≥300% with an acute increase of at least 44 µmol/L. KI was defined according to the modified Risk, Injury, Failure, Loss, End-stage kidney disease classification and comprised Valve Academic Research Consortium KI stages 1 through 3 for the purpose of this analysis. Renal impairment at baseline was defined by an estimated glomerular filtration rate according to the Cockroft-Gault formula of <60 mL/min. 5 Bleeding events were defined as life-threatening or disabling (1) in case of bleeding into a critical area or organ, or (2) bleeding causing hypovolemic shock or requiring vasopressors or surgery, or (3) with an overt source of bleeding with a decrease in hemoglobin ≥5 g/dL or packed red blood cells transfusion ≥4 units. Major bleeding was classified in the setting of overt bleeding associated with a decrease in the hemoglobin level of at least 3.0 g/dL. Major vascular access site complications involved access-related vascular injuries leading to either, death, need for blood transfusions (≥4 units), percutaneous or surgical intervention, or irreversible end-organ damage. Minor vascular complications were recorded in case of failure of percutaneous access site closure resulting in interventional or surgical vascular correction. For the purpose of this analysis, life-threatening bleeding and major access site complications were combined to a single composite event of ABC.
Statistical Analysis
We used MSA to estimate CV and non-CV mortality taking into account relevant short-and long-term events as summarized in the Valve Academic Research Consortium definitions. 4, 6 We present a model with 4 stages and 6 transitions ( Table 1) after pooling the stages stroke, CV death, and non-CV death: The stages TAVI, KI, ABC, and the composite of stroke and death allow 6 stage-to-stage transitions a patient may experience from the time of TAVI to death or end of followup. A clock forward approach of time scales was used, where duration
WHAT IS KNOWN
• Patients with severe aortic stenosis continue to experience compromised long-term survival despite successful transcatheter aortic valve implantation.
• Multistate Analysis provides an instrument to quantify transition-specific risk estimates of clinical events in disease progression.
WHAT THE STUDY ADDS
• The composite of stroke or death among transcatheter aortic valve implantation patients without intercurrent events is low over 3 years of follow-up.
• Low body mass index is a predictor of the composite of stroke or death after transcatheter aortic valve implantation, whereas secondary transitions from intercurrent access site or bleeding complications to stroke or death are predicted by advanced age, prior stroke, low body mass index, and atrial fibrillation. from 1 event to the next event moves forward with the patient, even if an intercurrent event occurs. As an example: if a patient after TAVI on March 2, 2012 developed KI on March 4, 2012 and then developed a stroke on the April 20, 2012, the duration of time between these stages will be 2 days and 49 days. The clock does not reset to zero each time a stage occurs. The patient is censored only at the very last event or because of end of follow-up. Transitions directly from TAVI to KI, ABC, stroke, or death are referred to as primary transitions (T1 to T3). Further transitions from KI and ABC to stroke or death are defined as secondary transitions (T4 to T6). The online-only Data Supplement  Table illustrates an exploratory comprehensive model including 6 disease stages and 14 stage-to-stage transitions.
The hazard ratio (HR) corresponding to each of these transitions was estimated using Cox proportional hazard models; transitionspecific HRs with 95% CIs are the only identifiable parameters in the MSA. However, we allowed for different baseline hazards for each transition and allowed the association of each baseline predictor to be different in each transition. Predictors were selected first using a univariate analysis taking into consideration all available clinical predictors such as age >80, female sex, TAVI access site, BMI ≤20 kg/m 2 , hypertension, current smoking, diabetes mellitus, hypercholesterolemia, coronary artery disease, prior myocardial infarction, prior percutaneous coronary intervention, prior coronary artery bypass graft surgery, prior stroke, peripheral vascular disease, chronic obstructive pulmonary disease, renal impairment (glomerular filtration rate <60 mL/min), prior pacemaker, atrial fibrillation, left ventricular ejection fraction ≤30%, and anemia. In the multivariable prediction model, a predictor was considered to be relevant only if at least 3 transition-specific HR were significant P≤0. 10 . The predictors in the multivariable model were TAVI access site, BMI≤20 kg/m 2 , prior stroke, and atrial fibrillation entered into the model along with age and sex. Based on transition-specific hazards, we predicted the transition probabilities; the probability of a particular event at a given time point given that they are alive at that specific time. The data were summarized as number of events and proportions within each transition. Analyses were performed using R version 2.12 (The R Development Core Team) using the mstate package. 7
Results
A total of 389 patients who underwent TAVI for severe aortic stenosis were included in this analysis. Median duration of follow-up was 1.1 years (interquartile range 6 months to 2.1 years) after truncation of follow-up at 3 years. Baseline characteristics are summarized in Table 2 . Men and women were equally distributed; mean age across the entire cohort was 82.4±5.8 years, and peri-interventional risk as assessed by logistic EuroSCORE and STS score averaged 24.3±14.2% and 6.8±5.3%, respectively. Table 3 shows imaging and procedural characteristics. A transfemoral access with either the Medtronic Core Valve or the Edwards-SAPIEN prosthesis was performed in 79.2% of patients; transapical and transsubclavian access was chosen in 19.5% and 1.6% of patients, respectively. Concomitant or staged percutaneous revascularization was performed in ≈25% of the patients.
MSA was used to estimate CV and non-CV mortality taking into account relevant short-and long-term events. Table 1 illustrates the matrix with 4 stages and 6 transitions a patient may experience from the time of TAVI to death or end of follow-up with cumulative event rates derived from MSA starting with TAVI until the end of follow-up among all 389 patients. An exploratory comprehensive MSA model with 6 disease stages and 14 stage-to-stage transitions is presented in the online-only Data Supplement Table. Out of 389 TAVI patients, 42.5% progressed via primary transitions to KI (9.5%), ABC (20.1%), or stroke and death (12.9%). Among patients who developed either peri-interventional KI or ABC, 40.5% and 41.0% died, respectively.
Significant transitions and transition-specific predictors derived from the MSA are summarized in the Figure. Taking into account all 4 disease stages, along their time of occurrence, we found 5 transitions to be relevant (3 primary transitions, 2 secondary transitions). Transapical access was a significant predictor for KI (hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.00-4.47) and ABC (HR, 1.78; 95% CI, 1.07-2.96), but had no impact on the composite of stroke and death. Low BMI (≤20 kg/m 2 ) increased the risk of stroke and death (HR, 2.64; 95% CI, 1.25-5.54). Age >80 years (HR, 3.15; 95% CI, 1.11-8.92), BMI ≤20 kg/m 2 (HR, 4.11; 95% CI, 1.33-12.70), prior stroke (HR, 16.42; 95% CI, 3.63-74.21), and presence of atrial fibrillation at baseline (HR, 4.12; 95% CI, 1.87-9.97) increased the risk of stroke and death after an intercurrent event of ABC. Transition-specific predictors of a comprehensive model are summarized in the online-only Data Supplement Figure and show similar results.
Discussion
This analysis quantifies transition-specific risk estimates of clinical events in disease progression after TAVI taking into account all events collectively rather than independently, and provides a holistic outcome assessment during long-term follow-up. The principal findings of the present study can be summarized as follows:
1. The cumulative risk of the composite event of stroke or death among patients without intercurrent events as determined by Valve Academic Research Consortium is low over 3 years of follow-up (12.9%). 2. BMI ≤20 kg/m 2 independently predicts the composite of stroke or death. 3. Transapical access increases the risk of KI and ABC. 4. The increased risk of stroke and death in patients experiencing ABC is predicted by advanced age (>80 years), BMI ≤20 kg/m 2 , prior stroke, and atrial fibrillation. Our analysis has certain limitations mostly inherent to the limited sample size and the duration of follow-up. The relatively low number of patients and events resulted in low power to detect potentially important associations and low precision as indicated by mostly wide CIs. In contrast, the statistical methodology applied in the present analysis provides a framework to derive robust risk estimates based on a clock forward approach as opposed to traditional analyses with focus on single events without consideration of the entire disease progression process.
A recent randomized trial comparing TAVI with a conservative strategy among patients with severe aortic stenosis considered as nonsurgical candidates reported a reduction of all-cause mortality from 50% to 31% in those undergoing aortic valve intervention during the first year: this is still 5 times the expected mortality rate in an age-matched group (6.3%) when compared with the general population. 8, 9 In the present analysis, we observed a mortality rate comparable to that of the general population only in those patients undergoing TAVI who did not have any intercurrent adverse event. Conversely, the risk of death increased several fold after intercurrent events such as KI, ABC, or stroke mirroring previously reported mortality rates of randomized controlled trials and registries, and corroborating the importance of peri-procedural complications on long-term prognosis. 1, 2, 9 In the absence of any intercurrent event, the risk of stroke or death was independently predicted by low BMI which has previously been identified as a predictor of all-cause mortality. 1, 2 Low BMI may represent a marker of frailty suggestive of a pattern similar to that of the obesity paradox observed among patients undergoing percutaneous coronary intervention. In addition to be a predictor of CV death, low BMI was also independently associated with an increased risk of stroke with the majority of cerebrovascular events occurring during the peri-procedural period (53% during first 7 days). This suggests that low BMI increases the risk of peri-procedural but not spontaneous stroke and is consistent with the report from a meta-analysis of healthy individuals 10 showing the absence of an association between low BMI and stroke. The underlying mechanism of low BMI leading to stroke may be explained by a higher vulnerability of smaller vessels to large-bore instruments or more cautious peri-procedural anticoagulation in underweight patients giving rise to thromboembolic events. Recent studies suggested an increased risk of stroke among female patients undergoing TAVI. Although female sex did not emerge as a risk factor of stroke in the present study, it is tempting to hypothesize that a lower BMI may have been more prevalent in female patients. However, in exploratory analyses we did not observe a difference in BMI between male and female patients, and there was no significant interaction between BMI and sex with respect to 30-day mortality. Notwithstanding, a much larger sample size would be required to address a potential effect modification by sex and BMI in the MSA.
The trend toward an increased risk of stroke and death among patients with atrial fibrillation did not reach statistical significance in a primary transition; however, atrial fibrillation was identified as a strong predictor of mortality after the occurrence of ABC. In the primary transition, the potential adverse impact of atrial fibrillation may have been camouflaged by therapeutic antithrombotic therapy, whereas a bleeding event may have led to discontinuation of antithrombotic therapy leading to thromboembolic complications and death. Likewise, advanced age (>80 years), BMI ≤20 kg/m 2 , and prior stroke were associated with an increased risk of stroke and death after intercurrent ABC.
In conclusion, applying MSA methodology we identified a low BMI as a primary predictor of stroke and mortality. Advanced age, low BMI, prior stroke, and atrial fibrillation increased the risk of stroke and death after an intercurrent event of ABC. Patients without the abovementioned risk factors have an excellent outcome similar to an age-matched control group and benefit the most from TAVI. Conversely, patients with 1 or more risk factors deserve careful evaluation and remain at increased risk for mortality after TAVI 
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Figure.
Predictors of stage-to-stage transitions in the condensed model. Hazard ratios (HRs) and 95% CI for the 4 primary transitions and 2 secondary transitions are summarized in a forest plot of transition-specific predictors during 3 years. The potential predictors of outcome were age>80 years, female sex, access site, body mass index (BMI) ≤20, hypercholesterolemia, prior myocardial infarction, prior coronary artery bypass graft, prior stroke, peripheral vascular disease, chronic obstructive pulmonary disease (COPD), renal impairment (estimated glomerular filtration rate [eGFR] <60 mL/ min), prior pacemaker implantation, atrial fibrillation, left ventricular ejection fraction (LVEF) ≤30%. A transition was considered in the multivariable model only if each predictor had at least 3 transition-specific hazard ratios with P≤0. 10 . In the multivariable predictor model, the predictors were age>80 years, female sex, access site, BMI≤20, prior stroke, and atrial fibrillation.
